Oncological outcomes of dose reductions in cisplatin due to renal dysfunction for patients with metastatic urothelial carcinoma.

Abstract

Authors

• Tetsushi Murakami
  Department of Urology Keio University School of Medicine Tokyo Japan.
• Eiji Kikuchi
  Department of Urology Keio University School of Medicine Tokyo Japan.
• Hiroki Ide
  Department of Urology Tokyo Saiseikai Central Hospital Tokyo Japan.
• Yuta Umezawa
  Department of UroOncology Saitama Medical University International Medical Center Saitama Japan.
• Takayuki Takahashi
  Department of UroOncology Saitama Medical University International Medical Center Saitama Japan.
• Mizuki Izawa
  Department of Urology Keio University School of Medicine Tokyo Japan.
• Kyohei Hakozaki
  Department of Urology National Hospital Organization Saitama Hospital Saitama Japan.
• Keisuke Shigeta
  Department of Urology Keio University School of Medicine Tokyo Japan.
• Koichiro Ogihara
  Department of Urology Kawasaki Municipal Hospital Kanagawa Japan.
• Hiroaki Kobayashi
  Department of Urology Saiseikai Yokohamashi Tobu Hospital Kanagawa Japan.
• Kunimitsu Kanai
  Department of Urology National Hospital Organization Saitama Hospital Saitama Japan.
• Takahiro Maeda
  Department of Urology Kawasaki Municipal Hospital Kanagawa Japan.
• Shunsuke Yoshimine
  Department of Urology Saitama City Hospital Saitama Japan.
• Ryuichi Mizuno
  Department of Urology Keio University School of Medicine Tokyo Japan.
• Koshiro Nishimoto
  Department of UroOncology Saitama Medical University International Medical Center Saitama Japan.
• Mototsugu Oya
  Department of Urology Keio University School of Medicine Tokyo Japan.

Keywords

No keywords available for this article.

External Resources